Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 184

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients

Open access
Szmania, Susann, Lapteva, Natalia, Garg, Tarun, Greenway, Amy, Lingo, Joshuah, Nair, Bijay, Stone, Katie, Woods, Emily, Khan, Junaid, Stivers, Justin, Panozzo, Susan, Campana, Dario, Bellamy, William T., Robbins, Molly, Epstein, Joshua, Yaccoby, Shmuel, Waheed, Sarah, Gee, Adrian, Cottler-Fox, Michele, Rooney, Cliona, Barlogie, Bart, van Rhee, Frits · 2015 · Journal of Immunotherapy

Abstract

Highly activated/expanded natural killer (NK) cells can be generated by stimulation with the human leukocyte antigen-deficient cell line K562, genetically modified to express 41BB-ligand and membrane-bound interleukin (IL)15. We tested the safety, persistence, and activity of expanded NK cells generated from myeloma patients (auto-NK) or haploidentical family donors (allo-NK) in heavily pretreated patients with high-risk relapsing myeloma. The preparative regimen comprised bortezomib only or bortezomib and immunosuppression with cyclophosphamide, dexamethasone, and fludarabine. NK cells were shipped overnight either cryopreserved or fresh. In 8 patients, up to 1×10⁸ NK cells/kg were infused on day 0 and followed by daily administrations of IL2. Significant in vivo expansion was observed only in the 5 patients receiving fresh products, peaking at or near day 7, with the highest NK-cell counts in 2 subjects who received cells produced in a high concentration of IL2 (500 U/mL). Seven days after infusion, donor NK cells comprised >90% of circulating leukocytes in fresh allo-NK cell recipients, and cytolytic activity against allogeneic myeloma targets was retained in vitro. Among the 7 evaluable patients, there were no serious adverse events that could be related to NK-cell infusion. One patient had a partial response and in another the tempo of disease progression decreased; neither patient required further therapy for 6 months. In the 5 remaining patients, disease progression was not affected by NK-cell infusion. In conclusion, infusion of large numbers of expanded NK cells was feasible and safe; infusing fresh cells was critical to their expansion in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/cji.0000000000000059

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 184

Metadata

Authors
Szmania, S., Lapteva, N., Garg, T., Greenway, A., Lingo, J., Nair, B., Stone, K., Woods, E., Khan, J., Stivers, J., Panozzo, S., Campana, D., Bellamy, W. T., Robbins, M., Epstein, J., Yaccoby, S., Waheed, S., Gee, A., Cottler-Fox, M., Rooney, C., Barlogie, B., & van Rhee, F.
Venue
Journal of Immunotherapy
Published
2015-01
Volume
38
Issue
1
Pages
24-36
ISSN
1524-9557 (ISSN-L)
OpenAlex
W1998007325
Cited by
184
References
2
FWCI
5.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients. https://app.cochat.ai/papers/10.1097/cji.0000000000000059
The paper
Szmania, S., Lapteva, N., Garg, T., Greenway, A., Lingo, J., Nair, B., Stone, K., Woods, E., Khan, J., Stivers, J., Panozzo, S., Campana, D., Bellamy, W. T., Robbins, M., Epstein, J., Yaccoby, S., Waheed, S., Gee, A., Cottler-Fox, M., . . . van Rhee, F. (2015). Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients. Journal of Immunotherapy. https://doi.org/10.1097/cji.0000000000000059

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.